Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
Peripheral T-cell non-Hodgkin's lymphomas are a diverse group of disorders, most of which carry a poor prognosis. Relapse is common following the administration of most currently available agents, and there are few effective options for salvage therapy. This article discusses a number of novel emerging therapies for the treatment of patients with T-cell non-Hodgkin's lymphomas, including the antimetabolite nelarabine, the purine nucleoside phosphorylase inhibitor forodesine, the pyrimidine analogue gemcitabine, and the fusion protein denileukin diftitox. Other therapies discussed for the treatment of patients with T-cell non-Hodgkin's lymphomas include bendamustine, gallium nitrate, and bortezomib, as well as the mammalian target of rapamycin inhibitors, small molecules that target the apoptotic pathways, immunomodulatory agents, and monoclonal antibodies.
Cheson
Bruce D
BD
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. bdc4@georgetown.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy*; D010936:Plant Extracts / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D010936:Plant Extracts; D011994:Recombinant Proteins